Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE

Charles C. Wykoff(Retina Consultants of Texas), Caroline R. Baumal(Eye Center), Anat Loewenstein(Tel Aviv University), Frank G. Holz(Universitäts-Augenklinik Bonn), Abhiram S. Vilupuru(Allergan (United States)), Jason Lin(Apellis Pharmaceuticals (United States)), Jeffrey S. Heier(Ophthalmic Consultants of Boston), Dilsher S. Dhoot(California Retina Consultants), David S. Boyer(Retina Vitreous Associates Medical Group), Jordi Monés(Barcelona Macula Foundation), Lejla Vajzovic(Duke University), Ashkan M. Abbey, Lawrence J. Singerman, Chao Li(Eli Lilly (United States)), Allen Chiang(Mid Atlantic Retina)
American Journal of Ophthalmology
April 23, 2025
10.1016/j.ajo.2025.04.016
Cited by 19

Related Papers

Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
|PubMed|2000|1.3k
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
|The Lancet|2023|420
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
|The Lancet|2023|343
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
|PubMed|2001|252
Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast
|American Journal Of Pathology|2001|250